207 related articles for article (PubMed ID: 24769543)
1. Macitentan does not interfere with hepatic bile salt transport.
Treiber A; Äänismaa P; de Kanter R; Delahaye S; Treher M; Hess P; Sidharta P
J Pharmacol Exp Ther; 2014 Jul; 350(1):130-43. PubMed ID: 24769543
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
[TBL] [Abstract][Full Text] [Related]
3. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.
Fattinger K; Funk C; Pantze M; Weber C; Reichen J; Stieger B; Meier PJ
Clin Pharmacol Ther; 2001 Apr; 69(4):223-31. PubMed ID: 11309550
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
[TBL] [Abstract][Full Text] [Related]
5. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation.
Stieger B
Handb Exp Pharmacol; 2011; (201):205-59. PubMed ID: 21103971
[TBL] [Abstract][Full Text] [Related]
6. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2.
Mano Y; Usui T; Kamimura H
Biopharm Drug Dispos; 2007 Jan; 28(1):13-8. PubMed ID: 17061295
[TBL] [Abstract][Full Text] [Related]
7. Effects of bile salt flux variations on the expression of hepatic bile salt transporters in vivo in mice.
Wolters H; Elzinga BM; Baller JF; Boverhof R; Schwarz M; Stieger B; Verkade HJ; Kuipers F
J Hepatol; 2002 Nov; 37(5):556-63. PubMed ID: 12399219
[TBL] [Abstract][Full Text] [Related]
8. Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver.
Hagenbuch N; Reichel C; Stieger B; Cattori V; Fattinger KE; Landmann L; Meier PJ; Kullak-Ublick GA
J Hepatol; 2001 Jun; 34(6):881-7. PubMed ID: 11451172
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity.
Leslie EM; Watkins PB; Kim RB; Brouwer KL
J Pharmacol Exp Ther; 2007 Jun; 321(3):1170-8. PubMed ID: 17374746
[TBL] [Abstract][Full Text] [Related]
10. Hepatic transport of bile salts.
Kullak-Ublick GA; Stieger B; Hagenbuch B; Meier PJ
Semin Liver Dis; 2000; 20(3):273-92. PubMed ID: 11076396
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs.
Mita S; Suzuki H; Akita H; Hayashi H; Onuki R; Hofmann AF; Sugiyama Y
Drug Metab Dispos; 2006 Sep; 34(9):1575-81. PubMed ID: 16760228
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Novel Fluorescent Bile Salt Derivatives for Studying Human Bile Salt and Organic Anion Transporters.
Leuenberger M; Häusler S; Höhn V; Euler A; Stieger B; Lochner M
J Pharmacol Exp Ther; 2021 Jun; 377(3):346-357. PubMed ID: 33782042
[TBL] [Abstract][Full Text] [Related]
13. A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects.
Li R; Niosi M; Johnson N; Tess DA; Kimoto E; Lin J; Yang X; Riccardi KA; Ryu S; El-Kattan AF; Maurer TS; Tremaine LM; Di L
Drug Metab Dispos; 2018 Apr; 46(4):346-356. PubMed ID: 29330218
[TBL] [Abstract][Full Text] [Related]
14. Physiological characteristics of allo-cholic acid.
Mendoza ME; Monte MJ; Serrano MA; Pastor-Anglada M; Stieger B; Meier PJ; Medarde M; Marin JJ
J Lipid Res; 2003 Jan; 44(1):84-92. PubMed ID: 12518026
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of bile salt and organic anion transporters in developing rat liver.
Gao B; St Pierre MV; Stieger B; Meier PJ
J Hepatol; 2004 Aug; 41(2):201-8. PubMed ID: 15288467
[TBL] [Abstract][Full Text] [Related]
16. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis.
Keitel V; Burdelski M; Warskulat U; Kühlkamp T; Keppler D; Häussinger D; Kubitz R
Hepatology; 2005 May; 41(5):1160-72. PubMed ID: 15841457
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of hepatic bile salt and organic anion transporters in pregnant and postpartum rats and the role of prolactin.
Cao J; Huang L; Liu Y; Hoffman T; Stieger B; Meier PJ; Vore M
Hepatology; 2001 Jan; 33(1):140-7. PubMed ID: 11124830
[TBL] [Abstract][Full Text] [Related]
18. Novel Bile Acid-Dependent Mechanisms of Hepatotoxicity Associated with Tyrosine Kinase Inhibitors.
Saran C; Sundqvist L; Ho H; Niskanen J; Honkakoski P; Brouwer KLR
J Pharmacol Exp Ther; 2022 Feb; 380(2):114-125. PubMed ID: 34794962
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat.
Treiber A; Schneiter R; Delahaye S; Clozel M
J Pharmacol Exp Ther; 2004 Mar; 308(3):1121-9. PubMed ID: 14617681
[TBL] [Abstract][Full Text] [Related]
20. Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists.
Kenna JG; Stahl SH; Eakins JA; Foster AJ; Andersson LC; Bergare J; Billger M; Elebring M; Elmore CS; Thompson RA
J Pharmacol Exp Ther; 2015 Feb; 352(2):281-90. PubMed ID: 25467130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
